Lilly Bolsters Radiopharmaceuticals Portfolio Through $1.1B Collaboration Deal with Aktis Oncology

Indianapolis, IN, May 21, 2024 (msn.com) -- In a strategic move to bolster its presence in the radiopharmaceuticals domain, Eli Lilly has forged a multi-target discovery collaboration agreement with Aktis Oncology, a privately held biotech firm. As part of this arrangement, Lilly will provide an initial payment of $60 million to Aktis, with the potential for further collaboration through milestone-based payments and royalties on sales, totaling $1.1 billion. This partnership grants Lilly exclusive global rights to develop targets for radiopharmaceuticals derived from Aktis' research, although it notably excludes Aktis' existing pipeline, which encompasses seven programs.

Read full article here.